Pipeline Selector helps you avoid
hours of painstaking research by quickly providing you with an accurate
snapshot of a single INN, including key patents, extensions and data
exclusivity expiry for 44 countries (7 country coverage also available),
regulatory issues and key players.
To
Read the Complete Report with TOC Visit:
http://www.marketresearchreports.biz/analysis-details/deferasirox-key-patent-spc-and-data-exclusivity-expiry-44-country-coverage
- This Pipeline Selector report
covers Deferasirox
- Deferasirox indications:
Treatment of chronic iron overload due to blood transfusions or in
patients with non-transfusion dependent thalassaemia; Management of
chronic iron overload in transfusion-dependent anaemias
- Deferasirox innovator: Novartis
(Exjade)
Examples of information found in this
online report include:
- Includes key patent
publications for 44 countries (see list below)
- Contains SPC protection for
every EU state plus patent term extensions in other countries
- Data exclusivity calculated on
a country by country basis
- Summary of dosage forms,
strengths, indications and active ingredient forms of the brand product
- DMF & Paragraph IV filings
- Litigation alerts
- Marketing authorisation holders
in selected territories
- Patent risk analysis via
graphical display of data from patent filings
- Hyper-linking to crucial patent
documents and national registries enabling data verification
To
Buy The Copy of This Report Visit
: http://www.marketresearchreports.biz/analysis/168916
Contact
M/s Sheela
90 Sate Street, Suite
700
Albany, NY 12207
USA – Canada Toll
Free: 866-997-4948
No comments:
Post a Comment